Navigation Links
Nanogen Issued Patent for Electronic Microarray With Memory

Nanogen, Inc. (Nasdaq: NGEN), developer of advanced diagnostic products, announced today that it was issued U.S. Patent No. 6,867,048, "Multiplexed Active Biologic Array" by the U.S. Patent and Trademark Office. The '048 patent relates to a method of addressing one or more electrodes (or "test sites") across multiple rows and columns of a microarray. The patent also covers a method for storing the value of the voltage associated with each electrode in a local memory. This "smart chip" technology is a key feature of Nanogen's NanoChip(R) 400 electronic microarray, the company's second generation multi-purpose system for developing and performing molecular diagnostic tests.

Using local memory circuits provides for precise control of the currents delivered to individual electrodes on the array, while minimizing the utilization of "off-chip" circuitry and overall system costs. The electric potential is controlled at each of the NanoChip's 400 test sites to move and concentrate DNA or RNA, providing accuracy, speed and flexibility for developing molecular diagnostic tests. Storing critical voltage information allows for precise control of the biological molecules during analysis and increases data management efficiency by tracking test site activation and array usage directly on the electronic microarray cartridge.

"This addition to our growing intellectual property portfolio illustrates our ability to develop differentiated advanced diagnostic products that add value to the company and to research and clinical laboratory customers," said Howard C. Birndorf, Nanogen chairman of the board and CEO.

This new patent expands Nanogen's intellectual property portfolio to include 114 patents issued in the U.S.

About Nanogen, Inc.

Nanogen's advanced diagnostics provide physicians and patients worldwide with sophisticated information to predict, diagnose and treat disease. Research and clinical reference labs use the highly accurate and relia ble NanoChip(R) Molecular Biology Workstation, NanoChip(R) Electronic Microarray and broad suite of analyte specific reagents to develop tests to detect infectious diseases, drug toxicity and mutations associated with cancer, cardiovascular and genetic diseases. The next generation instrument system, the NanoChip(R) 400, is expected to be available in 2005. Nanogen's subsidiary SynX offers a line of point-of-care diagnostic tests and is building expertise in cardiac related health conditions. Nanogen's ten years of pioneering research involving nanotechnology may also have future applications in medical diagnostics, biowarfare and other industries. For additional information please visit Nanogen's website at www.nanogen.com.


'"/>

Source:Nanogen


Related biology news :

1. Dinosaur DNA? New Patent Covers Degraded DNA recovery
2. Successful Test Of Single Molecule Switch Opens The Door To Biomolecular Electronics
3. Electronic chip, interacting with the brain, modifies pathways for controlling movement
4. Affymetrix Unveils Plans to Double Plant and Animal Genome Microarray Offering
5. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
6. Breakthrough Microarray-based Technology for the Study of Cancer
7. Characterizing Skin Cancer by Microarrays
8. Microarrays as phenotype
9. $6.5 Million Grant for Microarray Center at Yale School of Medicine
10. Agilent Technologies Introduces First Commercial Mouse Microarray for Comparative Genomic Hybridization Research
11. Genomatix Microarray Analysis Pipeline achieves Affymetrix GeneChip compatible?status
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/15/2016)... , April 15, 2016  A new partnership ... more accurate underwriting decisions in a fraction of ... competitively priced and high-value life insurance policies to ... With Force Diagnostics, rapid testing (A1C, ... data readings (blood pressure, weight, pulse, BMI, and ...
(Date:4/13/2016)...  IMPOWER physicians supporting Medicaid patients in ... standard in telehealth thanks to a new partnership with ... IMPOWER patients can routinely track key health measurements, such ... and, when they opt in, share them with IMPOWER ... local retail location at no cost. By leveraging this ...
(Date:3/29/2016)... , March 29, 2016 ... "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to ... ink used in a variety of writing instruments, ensuring ... of originally created collectibles from athletes on LegacyXChange will ... analysis of the DNA. Bill Bollander ...
Breaking Biology News(10 mins):
(Date:5/23/2016)... , May 23, 2016 Zimmer Biomet Holdings, Inc. ... today announced that its Board of Directors has approved the ... second quarter of 2016. The cash dividend ... July 29, 2016 to stockholders of record as of the ... dividends are subject to approval of the Board of Directors ...
(Date:5/23/2016)... CA (PRWEB) , ... May 23, 2016 , ... ... public interest organization focused on molecular nanotechnology, announced the winners for the 2015 ... pioneer physicist Richard Feynman, are given in two categories, one for experiment and ...
(Date:5/20/2016)... ... May 20, 2016 , ... Korean researchers say Manumycin A triggers apoptosis, ... new way to treat the disease. Surviving Mesothelioma has just posted an article on ... several Korean institutions based their mesothelioma study on the fact the Manumycin A, a ...
(Date:5/19/2016)... There is no saying when ... relentless pressures in pricing and lack in consumer confidence. ... though - numerous opportunities are up for grabs but ... presents four names in this sector: Portola Pharmaceuticals Inc. ... VTAE ), Anthera Pharmaceuticals Inc. (NASDAQ: ...
Breaking Biology Technology: